Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield
06:02am, Monday, 22'nd Sep 2025
Merck trades at 9.09x forward earnings, far below its 23.55x historical multiple and peers, while maintaining strong profitability and a 3.99% dividend yield. Blockbuster drug Keytruda, along with onc
Undercovered Dozen: Applied Digital, Merck, B2Gold And More
11:22am, Saturday, 20'th Sep 2025
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential. Among today's stocks covered are B2Gold, Me
What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill
04:46am, Saturday, 20'th Sep 2025
It is tempting for a dividend investor to simply select the highest yielding stocks. The problem with that approach is that it exposes you to the risk of dividend cuts if the yield is too high for the
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYT
US FDA approves Merck's new injectable version of Keytruda
02:36pm, Friday, 19'th Sep 2025
The U.S. Food and Drug Administration has approved a new formulation of Merck's blockbuster cancer therapy Keytruda that can be administered under the skin, offering a more convenient option of the wi
Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?
12:56pm, Friday, 19'th Sep 2025
Merck eyes new launches like Capvaxive and Winrevair, among others, to drive long-term growth as Keytruda nears loss of exclusivity.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
10:01am, Friday, 19'th Sep 2025
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Rate Cuts Could Actually Spark a Sell-Off: 5 Safe JP Morgan Dividend Stocks
10:00am, Friday, 19'th Sep 2025
Markets often rally in anticipation of rate cuts but then decline when the actual rate cuts are implemented.
EMA committee recommends approval for injectable version of Merck's Keytruda
07:15am, Friday, 19'th Sep 2025
The European Medicines Agency's committee has recommended the approval for a new formulation of Merck's blockbuster cancer therapy Keytruda that can be administered under the skin, the U.S. drugmaker
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of RSV in Infants During Their First RSV Season.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Produ
Rate Cuts Could Actually Spark a Sell-Off: 5 Safe JP Morgan Dividend Stocks
09:47am, Thursday, 18'th Sep 2025
Markets often rally in anticipation of rate cuts but then decline when the actual rate cuts are implemented.
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 2025
08:00am, Wednesday, 17'th Sep 2025
DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its mul
Oakmark Funds' Bill Nygren: Here's where to look beyond the Mag 7
04:38pm, Tuesday, 16'th Sep 2025
Bill Nygren, Oakmark Funds partner and CIO, joins CNBC's 'Closing Bell' to discuss where to find market opportunities outside of tech, why he's keeping an eye on Corebridge Financial and Delta Airline
Merck: Buy This Dividend Powerhouse While It's Cheap
01:22pm, Tuesday, 16'th Sep 2025
Merck offers a compelling opportunity for long-term income and value investors, trading near its 52-week low with a 4% dividend yield. MRK's robust drug pipeline, strong balance sheet, and strategic a
